SEC Form 4	
------------	--

Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

I	OMB Number: 3235-0287										
	Estimated average burden										
	hours per response:	0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or S	Sectior	n 30(h) c	of the	Investmer	nt Cor	mpany Act	of 1940							
1. Name and Address of Reporting Person <sup>*</sup> Bhatt Padmanabh P.						2. Issuer Name and Ticker or Trading Symbol <u>SUPERNUS PHARMACEUTICALS, INC.</u> [ SUPN ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify				vner	
(Last) (First) (Middle) C/O SUPERNUS PHARMACEUTICALS, INC.,						3. Date of Earliest Transaction (Month/Day/Year) 08/01/2024								Sr. VP of IP, CSO					
9715 KEY WEST AVENUE						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) ROCKVILLE MD 20850					Form filed by One Reporting Person Form filed by More than One Reporting Person														
(City)	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																		
		Tabl	e I - Nor	n-Deriv										ly Owned					
1. Title of Security (Instr. 3) Date (Month/D						Execution D		Date,	Code	Transaction Disposed Code (Instr. 5)		ties Acquir I Of (D) (Ins		Benefici Owned F	es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
										v	Amount	(A) o (D)	Price	Reported Transact (Instr. 3	ion(s)		(		
Common Stock									9,0	<b>9,001</b> <sup>(1)</sup>		D							
		Ta									osed of, onvertil			owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/D	n Date,	4. Transacti Code (Ins 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securitie: Beneficia Owned Following Reported Transacti (Instr. 4)	e Owners 5 Form: 1ly Direct ( or Indir 9 (I) (Inst	Ownership	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares						
Performance Share Unit	\$0	08/01/2024			Α		1,250		(2)		(2)	Common Stock	1,250	\$0	1,250	0	D		

Explanation of Responses:

1. Includes an aggregate of 431 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.

2. On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period.

/s/ Timothy C. Dec, as attorney-08/14/2024 in-fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.